| Previous Close | 3.29 |
| Open | 3.35 |
| Bid | 3.37 x 7300 |
| Ask | 3.38 x 5000 |
| Day's Range | 3.35 - 3.44 |
| 52 Week Range | 2.75 - 4.47 |
| Volume | 808,269 |
| Avg. Volume | 2,599,311 |
| Market Cap | 915.28M |
| Beta | 1.88 |
| PE Ratio (TTM) | -10.83 |
| EPS (TTM) | -0.31 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.60 |
- GlobeNewswire•5 hours ago
Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada
BEDMINSTER, N.J., DUBLIN, Ireland, and TORONTO, Sept. 25, 2017-- Amarin Corporation plc and HLS Therapeutics Inc., announced today an exclusive agreement between the parties to register, commercialize ...
- GlobeNewswire•5 days ago
Amarin to Present at Cantor Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 20, 2017-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...
- GlobeNewswire•12 days ago
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 13, 2017-- Amarin Corporation plc today announced that Mark W. Salyer has joined Amarin as Chief Commercial Officer. In this newly created position, Mr. Salyer ...
